“Gene Therapy Advancements”
One significant trend in the thalassemia market is the development and approval of gene therapies. These therapies aim to provide a long-term solution by addressing the root cause of thalassemia, rather than just managing symptoms. The approval of Zynteglo, a gene therapy for beta-thalassemia, has been a landmark in this field. This treatment uses the patient's own stem cells, which are modified to produce functional hemoglobin. It significantly reduces or eliminates the need for blood transfusions, offering hope for patients with severe forms of the disease. The increasing focus on gene therapies will revolutionize treatment, driving market growth and attracting significant investments.
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Alpha-thalassemia and Beta Thalassemia), Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, and Bone Marrow Transplants), End User (Hospitals and Clinics, Diagnostic Laboratories and Others) – Industry Trends and Forecast to 2032
.
The Global Thalassemia Market size was valued at USD 986.00 USD Million in 2024.
The Global Thalassemia Market is projected to grow at a CAGR of 16% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
